Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

RAB0210

Sigma-Aldrich

Mouse Granzyme B ELISA Kit

for serum, plasma and cell culture supernatant

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

UNSPSC Code:
41116158
NACRES:
NA.32

species reactivity

mouse

packaging

kit of 96 wells (12 strips x 8 wells)

technique(s)

ELISA: suitable
capture ELISA: suitable

input

sample type plasma
sample type serum
sample type cell culture supernatant(s)

assay range

inter-assay cv: <12%
intra-assay cv: <10%
sensitivity: 12 pg/mL
standard curve range: 14.34-3500 pg/mL

detection method

colorimetric

shipped in

wet ice

storage temp.

−20°C

Gene Information

mouse ... Gzmb(14939)

Categorías relacionadas

General description

The Mouse Granzyme B ELISA (Enzyme-Linked Immunosorbent Assay) kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of mouse Granzyme B in serum, plasma, cell culture supernatants and urine.
The Mouse Granzyme B enzyme-linked immunosorbent assay (ELISA) kit is an in vitro assay for the quantitative measurement of mouse granzyme B in serum, plasma, cell culture supernatants and urine. Granzyme B binds to mannose-6-phosphate/insulin-like growth factor II receptor. This protein is implicated in fast DNA fragmentation, a key step towards apoptosis in cells. Granzyme B is involved in the cleaving of pro-caspase-3, which leads to the activation of caspase-3. This protein also cleaves caspase-6, -7, -8, -9, and -10.

Immunogen

Recombinant Mouse Granzyme B

Application

For research use only. Not for use in diagnostic procedures.
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)

Other Notes

A sample Certificate of Analysis is available for this product.
Please type the word sample in the text box provided for lot number.

Los componentes del kit también están disponibles por separado

Referencia del producto
Descripción
SDS
  • RABELADAELISA 1X Assay/Sample Diluent Buffer A (Item D1)SDS
  • RABELADBELISA 5X Assay/Sample Diluent Buffer B (Item E1)SDS
  • RABSTOP3ELISA Stop Solution (Item I)SDS
  • RABTMB3ELISA Colorimetric TMB Reagent (HRP Substrate, Item H)SDS
  • RABWASH420X Wash Buffer (Item B)SDS

pictograms

Corrosion
GHS05

signalword

Warning

hcodes

H290

Hazard Classifications

Met. Corr. 1

Storage Class

8A - Combustible corrosive hazardous materials

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Brendan Bulik-Sullivan et al.
Nature biotechnology (2018-12-18)
Neoantigens, which are expressed on tumor cells, are one of the main targets of an effective antitumor T-cell response. Cancer immunotherapies to target neoantigens are of growing interest and are in early human trials, but methods to identify neoantigens either
Di Yang et al.
Scientific reports, 7(1), 1288-1288 (2017-04-30)
Systemic lupus erythematosus (SLE) features a decreased pool of CD4
Hee Joon Yoo et al.
Marine drugs, 17(8) (2019-08-01)
Immunomodulation involves two mechanisms, immunostimulation and immunosuppression. It is a complex mechanism that regulates the pathophysiology and pathogenesis of various diseases affecting the immune system. Immunomodulators can be used as immunostimulators to reduce the side effects of drugs that induce
Ciputra Adijaya Hartana et al.
PloS one, 13(7), e0200079-e0200079 (2018-07-03)
The immune system plays a significant role in urothelial bladder cancer (UBC) progression, with CD8+ T cells being capable to directly kill tumor cells using perforin and granzymes. However, tumors avoid immune recognition by escape mechanisms. In this study, we
Kosei Hasegawa et al.
Journal of immunotherapy (Hagerstown, Md. : 1997), 41(4), 201-207 (2018-02-13)
Cancer immunotherapy has now been established as a leading standard therapeutic option in a subset of patients with cancer. In this study, we conducted a phase I dose-escalation trial using a mixture of 5 peptides to vaccinate cervical cancer patients
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico